Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 4, 2008, Pages 533-543

  Medina, M ^a   Castro, A ^a  

^a Neuropharma SA   (Spain)

Author keywords

Alzheimer's disease; Bipolar disorder; Clinical trials; Diabetes; Drug development; GSK 3; Inhibitors; Lithium; NP 12; Protein kinase

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ARA 014418; AZD 1080; CAZPAULLONE; CHIR 99021; CT 20026; CT 98023; DCC 2036; DG 770; GLITAZONE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYMENIALDISINE; INDIRUBIN; LITHIUM; MALEIMIDE; MANZAMINE A; MERIDIANINE E; MERIOLIN; NNC 57 0558; NP 12; PALINURIN; PAULLONE DERIVATIVE; PYRAZOLE DERIVATIVE; SESQUITERPENOID; UDA 680; UNINDEXED DRUG; VALPROIC ACID; XD 4000;

ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN INFARCTION; CLINICAL TRIAL; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE MODEL; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GLUCOSE METABOLISM; HUMAN; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STROKE; STRUCTURE ANALYSIS;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46749128127     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem (1980) 107(2):519-527.
2. A) of the (Mg-ATP) dependent protein phosphatase. Eur J Biochem (1981) 119(3):443-451.
3. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J (1990) 9(8):2431-2438.
4. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J Neurochem (2002) 81(5):1073-1083.
5. Yu JY, Taylor J, DeRuiter SL, Vojtek AB, Turner DL: Simultaneous inhibition of GSK-3α and GSK-3β using hairpin siRNA expression vectors. Mol Ther (2003) 7(2):228-236.
6. Woodgett JR: Glycogen synthase kinase 3: An introductory synopsis. In: Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors - Drug Discovery and Development. Martínez A, Castro A, Medina M (Eds), John Wiley & Sons Inc, Hoboken, NJ, USA (2006):3-24.
7. Picton C, Woodgett J, Hemmings B, Cohen P: Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for phosphorylation of sites 3 by glycogen synthase kinase-3. FEBS Lett (1982) 150(1):191-196.
8. Hemmings BA, Resink TJ, Cohen P: Reconstitution of a Mg-ATP-dependent protein phosphatase and its activation through a phosphorylation mechanism. FEBS Lett (1982) 150(2):319-324.
9. Fiol CJ, Wang A, Roeske RW, Roach PJ: Ordered multisite protein phosphorylation. Analysis of glycogen synthase kinase 3 action using model peptide substrates. J Biol Chem (1990) 265(11):6061-6065.
10. Meijer L, Flajolet M, Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci (2004) 25(9):471-480.
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378(6559):785-789.
12. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P: Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem (1999) 274(24):17179-17183.
13. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci (2004) 29(2):95-102.
14. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA: Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol Cell Biol (2000) 20(24):9356-9363.
15. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB: Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol (2002) 22(7):2099-2110.
16. Sutherland C, Leighton IA, Cohen P: Inactivation of glycogen synthase kinase-3 beta by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem J (1993) 296(Pt 1):15-19.
17. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR: Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J (1993) 12(2):803-808.
18. 216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA (2000) 97(20):11074- 11079.
19. Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C: GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem (2004) 279(48):50176-50180.
20. Lockhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V: A chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophosphorylation. Mol Cell (2006) 24(4):627-633.
21. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3β: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105(6):721-732.
22. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J: Structure of GSK-3β reveals a primed phosphorylation mechanism. Nat Struct Biol (2001) 8(7):593-596.
23. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science (2004) 303(5665): 1800-1805.
24. ter Haar E: The crystal structures of glycogen synthase kinase 3. In: Glycogen Synthase Kinase-3 (GSK-3) and its Inhibitors - Drug Discovery and Development. Martínez A, Castro A, Medina M (Eds), John Wiley & Sons Inc, Hoboken, NJ, USA (2006):61-82.
25. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P: The selectivity of protein kinase inhibitors: A further update. Biochem J (2007) 408(3):297-315. •• The most recent, comprehensive review of the critical issue of the selectivity of protein kinase inhibitors. A series of 65 compounds were profiled against a panel of 70 to 80 kinases.
26. Patel DS, Dessalew N, Iqbal P, Bharatam PV: Structure-based approaches in the design of GSK-3 selective inhibitors. Curr Protein Pept Sci (2007) 8(4):352-364. •• A comprehensive review describing structure-based approaches using both molecular docking techniques and X-ray crystal structure information for the design of selective GSK-3 inhibitors.
27. Martínez A, Castro A, Medina M (Eds): Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors - Drug Discovery and Development. John Wiley & Sons Inc, Hoboken, NJ, USA (2006). •• The first book devoted entirely to GSK-3. Provides a comprehensive review of the role of GSK-3 in cell biology and physiology, and its identification as a molecular target for several important human pathologies, as well as the discovery and development of potent GSK-3 inhibitors.
28. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I: Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 56(1):70-78.
29. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP: The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol (2002) 103(2):91-99.
30. Medina M: Glycogen synthase kinase 3 (GSK-3) as a molecular target for Alzheimer's disease and other tauopathies. In: Neurodegenerative Diseases: From Molecular Concepts to Therapeutic Targets. von Bernhardi R, Inestrosa NC (Eds), Nova Science Publishers, Hauppauge, NY, USA (2008):93-110.
31. Avila J, Hernández F: GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 7(11):1527-1533.
32. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, Dewatcher I, Van Leuven F: Glycogen synthase kinase-3β, or a link between amyloid and tau pathology? Genes Brain Behav (2008) 7(Suppl 1):57-66. •• A very good review of specific aspects of GSK-3 in the context of recent in vivo data in AD animal models and the potential of GSK-3 as a therapeutic target for AD.
33. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K: Exposure of rat hippocampal neurons to amyloid β peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/ glycogen synthase kinase-3β. Neurosci Lett (1996) 203(1):33-36.
34. Ferreira A, Lu Q, Orecchio L, Kosik KS: Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ. Mol Cell Neurosci (1997) 9(3):220-234.
35. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K: Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc Natl Acad Sci USA (1993) 90(16):7789-7793.
36. Busciglio J, Yankner BA: Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature (1995) 378(6559):776-779.
37. Ribé EM, Pérez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sánchez B, Nieto M, Gómez-Ramos P et al: Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobio Dis (2005) 20(3):814-822.
38. Pérez M, Ribé E, Rubio A, Lim F, Morán MA, Ramos PG, Ferrer I, Isla MT, Avila J: Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation. Neuroscience (2005) 130(2):339-347.
39. Phiel CJ, Wilson CA, Lee VM, Klein PS: GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature (2003) 423(6938):435-439.
40. Twomey C, McCarthy JV: Presenilin-1 is an unprimed glycogen synthase kinase-3β substrate. FEBS Lett (2006) 580(17):4015-4020.
41. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH: In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3β. J Neurochem (1996) 67(2):699-707.
42. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E: Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci (2007) 27(8):1981-1991. • Describes an in vivo study demonstrating that modulation of the GSK-3 signaling pathway might also have neuroprotective effects by regulating amyloid precursor protein maturation and processing. This result further supports the notion that GSK-3 might be a suitable target for the treatment of AD.
43. Lee JH, Lau KF, Perkinton MS, Standen CL, Shemilt SJ, Mercken L, Cooper JD, McLoughlin DM, Miller CC: The neuronal adaptor protein X11α reduces Aβ levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem (2003) 278(47):47025-47029.
44. da Cruz e Silva EF, da Cruz e Silva AO: Protein phosphorylation and APP metabolism. Neurochem Res (2003) 28(10):1553-1561.
45. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P et al: LTP inhibits LTD in the hippocampus via regulation of GSK-3β. Neuron (2007) 53(5):703-717. •• Excellent study demonstrating the critical role that is played by GSK-3 in molecular mechanisms of synaptic plasticity during memory and learning processes.
46. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF et al: Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 25(1):81-86. •• Describes an in vivo study that implicates GSK-3 activity regulation during long-term potentiation in the hippocampus, suggesting that GSK-3 dysregulation may be an underlying factor of the cognitive dysfunction in various diseases, such Alzheimer's and other dementias.
47. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA (1996) 93(16):8455- 8459.
48. Chen G, Huang LD, Jiang YM, Manji HK: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem (1999) 72(3):1327-1330.
49. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees? Cell Mol Life Sci (2007) 64(16):2090-2103.
50. Jope RS: Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry (1999) 4(2):117-128.
51. Lenox RH, Hahn CG: Overview of the mechanism of action of lithium in the brain: Fifty-year update. J Clin Psychiatry (2000) 61(Suppl 9):5-15.
52. Gould TD, Manji HK: The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 8(5):497-511.
53. +-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA (1995) 92(11):5149-5153.
54. Ray WJ Jr, Szymanki ES, Ng L: The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta (1978) 522(2):434-442.
55. Stambolic V, Ruel L, Woodgett JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6(12):1664-1668.
56. 2+ concentration and inhibition of NMDA responses in cultured rat neurons. J Physiol (2001) 533(Pt 3):729-743.
57. Shaldubina A, Agam G, Belmaker RH: The mechanism of lithium action: State of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry (2001) 25(4):855-866.
58. Li X, Bijur GN, Jope RS: Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord (2002) 4(2):137-144.
59. Rowe MK, Wiest C, Chuang DM: GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 31(6):920-931.
60. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY: Dysfunction of protein kinase FA/GSK-3α in lymphocytes of patients with schizophrenic disorder. J Cell Biochem (1995) 59(1):108-116.
61. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry (2000) 157(5):831-833.
62. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M et al: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA (2005) 102(19):6990-6995.
63. Caccamo A, Oddo S, Tran LX, LaFerla FM: Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 170(5):1669-1675.
64. Nonaka S, Chuang DM: Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport (1998) 9(9):2081-2084.
65. Garcea G, Manson MM, Neal CP, Pattenden CJ, Sutton CD, Dennison AR, Berry DP: Glycogen synthase kinase-3β; A new target in pancreatic cancer? Curr Cancer Drug Targets (2007) 7(3):209-215.
66. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ: CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int (2008) 73(6):684-690.
67. Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA: Glycogen synthase kinase 3β (GSK-3β) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol (2007) 2(1):93-96.
68. Martinez A: Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs. Med Res Rev (2008): epublished ahead of print. DOI:10.1002/med.20119.
69. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J et al: Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol (2000) 7(1):51-63.
70. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G et al: Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem (2001) 276(1):251-260.
71. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, Gussio R et al: Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur J Biochem (2000) 267(19):5983-5994.
72. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D et al: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol (2000) 7(10):793-803.
73. Witherington J, Bordas V, Garland SL, Hickey DM, Ife RJ, Liddle J, Saunders M, Smith DG, Ward RW: 5-Aryl-pyrazolo[3,4-b] pyridines: Potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett (2003) 13(9):1577-1580.
74. Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, Radesäter AC, Jerning E, Markgren PO, Borgegård T, Nylöf M et al: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 278(46):45937-45945.
75. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ: First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem (2002) 45(6):1292-1299.
76. Martinez A, Alonso M, Castro A, Dorronsoro I, Gelpí JL, Luque FJ, Pérez C, Moreno FJ. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem (2005) 48(23):7103-7112.
77. Yost C, Farr GH III, Pierce SB, Ferkey DM, Chen MM, Kimelman D: GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 93(6):1031-1041.
78. Kaidanovich-Beilin O, Eldar-Finkelman H: Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: Molecular characterization in liver and muscle. J Pharmacol Exp Ther (2006) 316(1):17-24.
79. Dorronsoro I, Castro A, Martinez A: Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs? Expert Opin Ther Patents (2002) 12(10):1527-1536.
80. Wagman AS, Johnson KW, Bussiere DE: Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des (2004) 10(10):1105-1137.
81. Dokken BB, Henriksen EJ: Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. Am J Physiol Endocrinol Metab (2006) 291(2):E207-E213.
82. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M: Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med (2006) 12(1):89-98.
83. Romagnani P, Lasagni L, Mazzinghi B, Lazzeri E, Romagnani S: Pharmacological modulation of stem cell function. Curr Med Chem (2007) 14(10):1129-1139.
84. Eom TY, Roth KA, Jope RS: Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem (2007) 282(31):22856-22864. •• Apoptosis of neural precursor cells induced by trophic factor withdrawal or genotoxic stress can be reversed by GSK-3 inhibitors. Mechanisms controlling neural precursor cell survival are critical during brain development, for neuron replenishment in adults and for neuron replacement after transplantation.
85. Witherington J: 3-Amino pyrazoles as potent and selective glycogen kinase synthase 3 (GSK-3) inhibitors. In: Glycogen Synthase Kinase-3 (GSK-3) and its Inhibitors - Drug Discovery and Development. Martínez A, Castro A, Medina M (Eds), John Wiley & Sons Inc, Hoboken, NJ, USA (2006):281-306.
86. Gould TD, Einat H, Bhat R, Manji HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 7(4):387-390.
87. Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond SY, Duka T, Rusnak M, Sidhu A: Highly potent and speci?c GSK-3βinhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem (2006) 1(2):256-266.
88. Gross ER, Hsu AK, Gross GJ: Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase 3β. Diabetes (2007) 56(1):127-136.
89. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E et al: Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4- tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2, 5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J Med Chem (2004) 47(16):3934-3947.
90. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ et al: Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res (2006) 21(6):910-920.
91. Stukenbrock H, Mussmann R, Geese M, Ferandin Y, Lozach O, Lemcke T, Kegel S, Lomow A, Burk U, Dohrmann C, Meijer L et al: 9-Cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic β-cell protection and replication. J Med Chem (2008) 51(7):2196-2207.
92. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J: Glycogen synthase kinase 3β (GSK-3β) mediates 6-hydroxydopamine-induced neuronal death. FASEB J (2004) 18(10):1162-1164.
93. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A: Regulation of inflammatory response in neuronal cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator activated receptor γ activation. J Biol Chem (2005) 280(22):21453-21462.
94. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT: Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood (2007) 110(13):4436-4444.
95. Dugo L, Collin M, Thiemermann C: Glycogen synthase kinase 3β as a target for the therapy of shock and inflammation. Shock (2007) 27(2):113-123. • Very good review which presents the latest studies describing the effects of GSK-3 inhibition as a potential target for the therapy of diseases associated with inflammation, ischemia/reperfusion and shock.
96. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A: NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. J Neurosci (2007) 27(21):5766-5776.
97. Gompel M, Leost M, De Kier Joffe EB, Puricelli L, Franco LH, Palermo J, Meijer L: Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg Med Chem Lett (2004) 14(7):1703-1707.
98. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C et al: GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 10(12):1255-1266.
99. Alonso D, Martinez A: Marine compounds as a new source for glycogen synthase kinase 3 inhibitors. In: Glycogen Synthase Kinase-3 (GSK-3) and its Inhibitors - Drug Discovery and Development. Martínez A, Castro A, Medina M (Eds), John Wiley & Sons Inc, Hoboken, NJ, USA (2006):307-331.
100. Hamann M, Alonso D, Martín-Aparicio E, Fuertes A, Pérez-Puerto MJ, Castro A, Morales S, Navarro ML, Del Monte-Millán M, Medina M, Pennaka H et al: Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod (2007) 70(9):1397-1405.
101. Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clément M, Valette A, Liger F, Marquet B, Morris JC, Endicott JA, Joseph B et al: Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/ meriolin complex. J Med Chem (2008) 51(4):737-751.
102. Gadakar PK, Phukan S, Dattatreya P, Balaji VN: Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3β. J Chem Inf Model (2007) 47(4):1446-1459. • Describes molecular docking studies as a useful tool for the identification of new potential inhibitors.
103. Shin D, Lee SC, Heo YS, Lee WY, Cho YS, Kim YE, Hyun YL, Cho JM, Lee YS, Ro S: Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3β. Bioorg Med Chem Lett (2007) 17(20):5686-5689.
104. Mazanetz MP, Fischer PM: Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 6(6):464-479. •• Very good review describing progress toward the design of potent, selective CDK5, GSK-3 and ERK2 inhibitors.
105. Kim HJ, Choo H, Cho YS, No KT, Pae AN: Novel GSK-3β inhibitors from sequential virtual screening. Bioorg Med Chem (2008) 16(2):636-643.
106. Dessalew N, Bharatam PV: Structure based de novo design of novel glycogen synthase kinase 3 inhibitors. Bioorg Med Chem (2007) 15(11):3728-3736.
107. Dessalew N, Bharatam PV: Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening. Chem Biol Drug Des (2006) 68(3):154-165.
108. Duchowicz PR, Castro EA: QSAR studies for the pharmacological inhibition of glycogen synthase kinase-3. Med Chem (2007) 3(4):393-417. • Recent review that summarizes the available QSAR information that is useful in the design of new inhibitors.
109. Dessalew N, Patel DS, Bharatam PV: 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase 3β inhibitors. J Mol Graph Model (2007) 25(6):885-895.
110. Clinical Trials.gov: US National Institutes of Health, Bethesda, MD, USA. www.clinicaltrials.gov
111. Zhong J, Lee WH: Lithium: A novel treatment for Alzheimer's disease? Exp Opin Drug Saf (2007) 6(4):375-383.
112. National Institute on Aging (NIA): New Alzheimer's clinical trials to be undertaken by NIA nationwide consortium. Press Release (2006) October 17. www.nia.nih.gov/NewsAndEvents/PressReleases/PR20061017ADCS.htm
113. MacDonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S: A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008): epublished ahead of print. DOI:10.1002/gps.1964. • First published study to assess the safety of prescribing long-term lithium to elderly people with AD. The therapeutic potential of lithium in this pathology is discussed and highlights potential adverse effects, contraindications in the target population and the risk of serious toxicity.
114. AstraZeneca pipeline summary: AstraZeneca, London, UK (2008). www.astrazeneca.com/article/511390.aspx
115. Neuropharma: Neuropharma introduces in clinical trials its first medicine for the treatment of alzheimer's. Press release (2006) April 24.
116. TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT LP (Eldar-Finkelman H, Portnoy M): Glycogen synthase kinase-3 inhibitors. WO-2006054298 (2006).
117. TEL AVIV UNIVERSITY (Eldar-Finkelman H): Glycogen synthase kinase-3 inhibitors. WO-00149709 (2001).